Bio-Techne

US · TECH #1365 by market cap Listed 1970

72.53 +0.10 +0.14%

Live - 5344 symbols - heartbeat 183s ago · 2026-10-08 07:40

Pre-market 72.53 0.00%

After-hours 72.53 0.00%

Market cap: 11.37B
P/E (TTM): 62.53
P/B: 5.39
EPS: 1.16
Div yield: 0.44%
52W pos: 99%

Reader sentiment Are you bullish or bearish on TECH?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Financial Health how this is computed

Good

Altman Z-Score is 15.97, above the 3.0 "safe zone" threshold.
Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 8 years

Latest year -0.38% YoY

Margins

Gross margin: 65.77%
Operating margin: 22.44%
Net margin: 14.97%

Key ratios & quality

Enterprise value: 11.32B
Altman Z-Score: 15.97

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item	2019	2020	2021	2022	2023	2024	2025	2026
Revenue	714.01M	738.69M	931.03M	1.11B	1.14B	1.16B	1.22B	1.22B
Gross profit	473.49M	483.19M	632.85M	756.50M	769.82M	769.73M	790.27M	799.07M
Selling & admin expenses	236.87M	240.88M	289.92M	339.00M	352.44M	393.32M	415.10M	406.67M
Research & development	62.41M	65.19M	70.60M	87.14M	92.49M	96.66M	99.50M	94.77M
Operating profit	147.10M	148.85M	242.69M	295.83M	291.00M	246.40M	242.80M	272.61M
Pretax profit	112.02M	276.48M	148.18M	301.39M	338.66M	185.69M	98.46M	240.68M
Tax	15.94M	47.18M	8.59M	38.29M	53.22M	17.58M	25.06M	58.82M
Net profit	96.07M	229.30M	139.59M	263.10M	285.44M	168.11M	73.40M	181.86M
Basic EPS	1	2	1	2	2	1	0	1
Diluted EPS	0.62	1.46	0.87	1.66	1.76	1.05	0.46	1.16

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Revenue	316.18M	316.96M	286.56M	295.88M	311.42M	321.19M
Gross profit	214.56M	198.81M	188.11M	191.28M	208.29M	211.39M
Selling & admin expenses	151.27M	23.22M	116.21M	113.69M	109.34M	67.43M
Research & development	24.58M	26.03M	24.24M	23.13M	23.46M	23.95M
Operating profit	38.71M	116.69M	47.66M	54.46M	75.50M	95.00M
Pretax profit	38.27M	-22.86M	47.99M	50.78M	71.23M	70.68M
Tax	15.69M	-5.18M	9.81M	12.78M	20.18M	16.06M
Net profit	22.59M	-17.68M	38.19M	38.01M	51.05M	54.62M
Basic EPS	0	0	0	0	0	0
Diluted EPS	0.14	-0.11	0.24	0.24	0.32	0.35

Balance sheet

Line item	2019	2020	2021	2022	2023	2024	2025	2026
Total current assets	412.61M	520.92M	510.61M	605.56M	621.48M	617.42M	608.30M	744.40M
Cash & ST investments	166.03M	270.89M	231.55M	247.03M	204.31M	152.86M	162.19M	264.71M
Inventory	91.05M	103.15M	116.75M	141.12M	171.64M	179.73M	189.45M	195.74M
Total assets	1.88B	2.03B	2.26B	2.29B	2.64B	2.70B	2.56B	2.59B
Total current liabilities	101.99M	106.67M	152.28M	176.02M	128.51M	159.38M	175.85M	163.70M
Short-term debt	12.50M	22.04M	24.10M	24.43M	11.20M	12.92M	14.10M	14.94M
Long-term debt	492.66M	344.24M	328.83M	243.41M	350.00M	319.00M	346.00M	200.00M
Total liabilities	718,821,000.00	646,397,000.00	691,723,000.00	593,794,000.00	672,176,000.00	635,017,000.00	639,060,000.00	478,505,000.00
Total equity	1.17B	1.38B	1.57B	1.70B	1.97B	2.07B	1.92B	2.11B
Retained earnings	931.93M	1.06B	1.09B	1.12B	1.31B	1.33B	1.07B	1.14B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Total current assets	627.24M	608.30M	609.51M	637.43M	688.05M	744.40M
Cash & ST investments	140.67M	162.19M	144.96M	172.88M	209.82M	264.71M
Inventory	191.08M	189.45M	203.19M	205.45M	201.18M	195.74M
Total assets	2.64B	2.56B	2.53B	2.52B	2.55B	2.59B
Total current liabilities	169.20M	175.85M	144.55M	140.43M	153.28M	163.70M
Short-term debt	14.05M	14.10M	13.77M	13.71M	14.18M	14.94M
Long-term debt	330.00M	346.00M	300.00M	260.00M	200.00M	200.00M
Total liabilities	626,234,000.00	639,060,000.00	560,334,000.00	511,710,000.00	465,297,000.00	478,505,000.00
Total equity	2.02B	1.92B	1.97B	2.01B	2.09B	2.11B
Retained earnings	1.20B	1.07B	1.08B	1.11B	1.15B	1.14B

Cash flow

Line item	2019	2020	2021	2022	2023	2024	2025	2026
Operating cash flow	181.62M	205.22M	352.16M	325.27M	254.39M	298.98M	287.56M	292.07M
Depreciation & amortization	78.17M	82.74M	87.75M	101.07M	107.24M	111.71M	109.90M	97.36M
Free cash flow	156.21M	153.47M	307.86M	280.36M	216.15M	236.10M	256.55M	263.22M
Dividends paid	-48.36M	-48.90M	-49.62M	-50.19M	-50.29M	-50.42M	-50.39M	-49.92M
Stock buybacks / issuance	-15.41M	-50.11M	-43.18M	-160.95M	-19.56M	-80.04M	-275.73M	-41.68M
Ending cash balance	100.89M	146.63M	199.09M	172.57M	180.57M	151.79M	162.19M	264.71M

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Operating cash flow	41.12M	98.20M	27.59M	82.41M	86.66M	95.42M
Depreciation & amortization	27.57M	27.11M	24.34M	24.71M	24.17M	24.14M
Free cash flow	31.00M	93.31M	22.22M	76.49M	77.58M	86.94M
Dividends paid	-12.58M	-12.39M	-12.44M	-12.47M	-12.52M	-12.48M
Stock buybacks / issuance	-100.05M	-100.06M	-24.00K	0	0	-41.65M
Ending cash balance	140.67M	162.19M	144.96M	172.88M	209.82M	264.71M

Returns & efficiency

Line item	2019	2020	2021	2022	2023	2024	2025	2026
ROE %	8.55	17.99	9.53	16.66	15.55	8.33	3.68	9.03
ROA %	5.52	11.71	6.54	11.93	11.56	6.29	2.79	7.07
ROIC %	7.36	14.03	8.06	14.02	13.12	7.30	3.17	7.81
5-year avg ROE %	10.90	11.88	11.36	13.03	13.66	13.61	10.75	10.65
EBIT margin %	18.73	40.03	17.41	28.28	30.78	17.38	8.77	20.60
FCF / sales %	21.88	20.78	33.07	25.36	19.02	20.37	21.04	21.66
Current ratio	4.05	4.88	3.35	3.44	4.84	3.87	3.46	4.55
Quick ratio	2.98	3.69	2.48	2.51	3.29	2.47	2.10	2.94
Debt / assets	26.81	21.38	18.58	14.20	17.24	15.52	17.36	11.18
LT debt / equity	42.27	29.79	25.37	17.72	22.57	19.65	22.41	13.00
Interest coverage	6.16	15.40	11.62	27.65	31.20	12.80	12.57	25.99
Revenue CAGR (3Y) %	12.68	9.48	13.13	15.69	15.45	7.58	3.33	2.25
Net income CAGR (3Y) %	-2.76	44.44	3.63	41.48	7.55	6.18	-35.38	-13.93
FCF CAGR (3Y) %	7.07	6.09	27.24	21.53	12.09	-8.47	-2.92	6.79

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
ROE %	6.53	3.68	3.80	3.96	5.34	9.03
ROA %	4.91	2.79	2.96	3.12	4.22	7.07
ROIC %	5.47	3.17	3.34	3.52	4.74	7.81
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	14.21	8.77	9.50	10.16	12.95	20.60
FCF / sales %	18.26	21.04	18.41	18.35	22.27	21.66
Current ratio	3.71	3.46	4.22	4.54	4.49	4.55
Quick ratio	2.23	2.10	2.28	2.55	2.77	2.94
Debt / assets	16.02	17.36	15.62	13.91	11.38	11.18
LT debt / equity	20.29	22.41	19.37	16.77	13.24	13.00
Interest coverage	19.44	12.57	12.47	13.29	16.19	25.99
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

✦ Quant Revenue Concentration how this is computed

Single-engine

Protein Sciences is the largest reported line at 71.98% of revenue, across 4 reported segments.
The next-largest line, Diagnostics and Spatial Biology, is a distant second at 27.68% - a sharp slowdown here would have little to offset it.

Revenue breakdown most recent period

Business

Protein Sciences71.98%

Diagnostics and Spatial Biology27.68%

Other revenue0.45%

Region

United States52.29%

EMEA, excluding United Kingdom24.22%

Greater China8.56%

Asia Pacific, excluding Greater China7.06%

United Kingdom4.63%

Rest of world3.23%

Quote time 2026-10-08 07:40:17 · For reference only, not investment advice and not tailored to your situation.